Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

JAMA - Journal of the American Medical Association

Volumn 323, Issue 22, 2020, Pages 2310-2328

  Patnode, Carrie D ^a   Perdue, Leslie A ^a   Rushkin, Megan ^a   Dana, Tracy ^b   Blazina, Ian ^b   Bougatsos, Christina ^b   Grusing, Sara ^b   O'Connor, Elizabeth A ^a   Fu, Rongwei ^b   Chou, Roger ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; OPIATE AGONIST; NALOXONE; NARCOTIC ANTAGONIST;

DISEASE SURVEILLANCE; DRUG DEPENDENCE; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MASS SCREENING; MEASUREMENT ACCURACY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; ADVERSE EVENT; FEMALE; PRACTICE GUIDELINE; PREGNANCY; PROCEDURES; PSYCHOTHERAPY; QUESTIONNAIRE; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; FEMALE; HUMANS; MASS SCREENING; NALOXONE; NARCOTIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PSYCHOTHERAPY; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 85086032214     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.21381     Document Type: Review

References (146)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004; 291 (10): 1238-1245. doi: 10.1001/jama.291.10.1238 15010446
2. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013; 369 (5): 448-457. doi: 10.1056/NEJMra1201534 23902484
3. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: detailed tables. Published August 2019. Accessed May 7, 2020. https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables
4. US Preventive Services Task Force. Final recommendation statement: drug use, illicit: screening. Published 2008. Accessed September 11, 2018. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/drug-use-illicit-screening
5. Polen MR, Whitlock EP, Wisdom JP, Nygren P, Bougatsos C. Screening in Primary Care Settings for Illicit Drug Use: Staged Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 58, Part 1. Agency for Healthcare Research and Quality; January 2008. AHRQ publication 08-05108-EF-s.
6. Lanier D, Ko S. Screening in Primary Care Settings for Illicit Drug Use: Assessment of Screening Instruments: A Supplemental Evidence Update for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 2008. AHRQ publication 08-05108-EF-2.
7. Patnode CD, Perdue LA, Rushkin M, O'Connor EA. Screening for Drug Use in Primary Care in Adolescents and Adults, Including Pregnant Women: An Updated Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 186. Agency for Healthcare Research and Quality; 2019. AHRQ publication 19-05255-EF-1.
8. Chou R, Dana T, Blazina I, Grusing S, Bougatsos C. Interventions for Drug Use-Supplemental Report: A Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 187. Agency for Healthcare Research and Quality; 2019.
9. Tiet QQ, Leyva YE, Browne K, Moos RH. Screen of drug use: diagnostic accuracy for cannabis use disorder. Addict Behav. 2019; 95: 184-188. doi: 10.1016/j.addbeh.2019.02.010 30933714
10. Tiet QQ, Leyva YE, Moos RH. Screen of drug use: diagnostic accuracy for opioid use disorder. Drug Alcohol Depend. 2019; 198: 176-179. doi: 10.1016/j.drugalcdep.2019.01.044 30947051
11. Ondersma SJ, Chang G, Blake-Lamb T, Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019; 114 (9): 1683-1693. doi: 10.1111/add.14651 31216102
12. Coleman-Cowger VH, Oga EA, Peters EN, Trocin KE, Koszowski B, Mark K. Accuracy of three screening tools for prenatal substance use. Obstet Gynecol. 2019; 133 (5): 952-961. doi: 10.1097/AOG.0000000000003230 30969217
13. Knight JR, Sherritt L, Gibson EB, Effect of computer-based substance use screening and behavioral counseling vs. usual care for youths in pediatric primary care: a pilot randomized clinical trial. JAMA Netw Open. 2019; 2 (6):
14. United States Department of Veterans Affairs. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Published 2015. Accessed April 26, 2019. https://www.healthquality.va.gov/guidelines/MH/sud/VADODSUDCPGRevised22216.pdf
15. US Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. Agency for Healthcare Research and Quality; 2015.
16. Berkman ND, Lohr KN, Ansari M, Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update. In: Agency for Healthcare Research and Quality, ed. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality; 2014: 314-349. AHRQ publication 10(14)-EHC063-EF.
17. Kelly SM, Gryczynski J, Mitchell SG, Kirk A, O'Grady KE, Schwartz RP. Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use. Pediatrics. 2014; 133 (5): 819-826. doi: 10.1542/peds.2013-2346 24753528
18. McNeely J, Strauss SM, Saitz R, A brief patient self-administered substance use screening tool for primary care: two-site validation study of the Substance Use Brief Screen (SUBS). Am J Med. 2015; 128 (7): 784.e9-784.e19. doi: 10.1016/j.amjmed.2015.02.007 25770031
19. Tiet QQ, Leyva YE, Moos RH, Frayne SM, Osterberg L, Smith B. Screen of drug use: diagnostic accuracy of a new brief tool for primary care. JAMA Intern Med. 2015; 175 (8): 1371-1377. doi: 10.1001/jamainternmed.2015.2438 26075352
20. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010; 170 (13): 1155-1160. doi: 10.1001/archinternmed.2010.140 20625025
21. Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002; 156 (6): 607-614. doi: 10.1001/archpedi.156.6.607 12038895
22. Chasnoff IJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's Plus screen for substance use in pregnancy validation of the 4P's Plus. J Perinatol. 2007; 27 (12): 744-748. doi: 10.1038/sj.jp.7211823 17805340
23. Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract. 2001; 14 (2): 95-106. 11314930
24. McCann BS, Simpson TL, Ries R, Roy-Byrne P. Reliability and validity of screening instruments for drug and alcohol abuse in adults seeking evaluation for attention-deficit/hyperactivity disorder. Am J Addict. 2000; 9 (1): 1-9. doi: 10.1080/10550490050172173 10914288
25. McNeely J, Wu LT, Subramaniam G, Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016; 165 (10): 690-699. doi: 10.7326/M16-0317 27595276
26. Kumar PC, Cleland CM, Gourevitch MN, Accuracy of the Audio Computer Assisted Self Interview version of the Alcohol, Smoking and Substance Involvement Screening Test (ACASI ASSIST) for identifying unhealthy substance use and substance use disorders in primary care patients. Drug Alcohol Depend. 2016; 165: 38-44. doi: 10.1016/j.drugalcdep.2016.05.030 27344194
27. Harris SK, Knight JR Jr, Van Hook S, Adolescent substance use screening in primary care: validity of computer self-administered versus clinician-administered screening. Subst Abus. 2016; 37 (1): 197-203. doi: 10.1080/08897077.2015.1014615 25774878
28. Lam LP, Leung WC, Ip P, Validation of the Drug Abuse Screening Test (DAST-10): a study on illicit drug use among Chinese pregnant women. Sci Rep. 2015; 5: 11420. doi: 10.1038/srep11420 26091290
29. Gryczynski J, Kelly SM, Mitchell SG, Kirk A, O'Grady KE, Schwartz RP. Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients. Addiction. 2015; 110 (2): 240-247. doi: 10.1111/add.12767 25311148
30. Legleye S, Guignard R, Richard JB, Ludwig K, Pabst A, Beck F. Properties of the Cannabis Abuse Screening Test (CAST) in the general population. Int J Methods Psychiatr Res. 2015; 24 (2): 170-183. doi: 10.1002/mpr.1465 26077195
31. Mitchell SG, Kelly SM, Gryczynski J, The CRAFFT cut-points and DSM-5 criteria for alcohol and other drugs: a reevaluation and reexamination. Subst Abus. 2014; 35 (4): 376-380. doi: 10.1080/08897077.2014.936992 25036144
32. Bastiani L, Siciliano V, Curzio O, Optimal scaling of the CAST and of SDS Scale in a national sample of adolescents. Addict Behav. 2013; 38 (4): 2060-2067. doi: 10.1016/j.addbeh.2012.12.016 23396173
33. Ondersma SJ, Svikis DS, LeBreton JM, Development and preliminary validation of an indirect screener for drug use in the perinatal period. Addiction. 2012; 107 (12): 2099-2106. doi: 10.1111/j.1360-0443.2012.03982.x 22882721
34. Fernandez-Artamendi S, Fernández-Hermida JR, Muñiz-Fernández J, Secades-Villa R, García-Fernández G. Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires. Subst Abuse Treat Prev Policy. 2012; 7: 13. doi: 10.1186/1747-597X-7-13 22471908
35. Legleye S, Piontek D, Kraus L. Psychometric properties of the Cannabis Abuse Screening Test (CAST) in a French sample of adolescents. Drug Alcohol Depend. 2011; 113 (2-3): 229-235. doi: 10.1016/j.drugalcdep.2010.08.011 20869178
36. Grekin ER, Svikis DS, Lam P, Drug use during pregnancy: validating the Drug Abuse Screening Test against physiological measures. Psychol Addict Behav. 2010; 24 (4): 719-723. doi: 10.1037/a0021741 21198230
37. Dawson DA, Compton WM, Grant BF. Frequency of 5+/4+ drinks as a screener for drug use and drug-use disorders. J Stud Alcohol Drugs. 2010; 71 (5): 751-760. doi: 10.15288/jsad.2010.71.751 20731982
38. Lane WG, Dubowitz H, Feigelman S, Screening for parental substance abuse in pediatric primary care. Ambul Pediatr. 2007; 7 (6): 458-462. doi: 10.1016/j.ambp.2007.07.007 17996841
39. Harrison PA, Godecker A, Sidebottom A. Validity of the prenatal risk overview for detecting drug use disorders in pregnancy. Public Health Nurs. 2012; 29 (6): 563-573. doi: 10.1111/j.1525-1446.2012.01030.x 23078427
40. D'Amico EJ, Parast L, Meredith LS, Ewing BA, Shadel WG, Stein BD. Screening in primary care: what is the best way to identify at-risk youth for substance use? Pediatrics. 2016; 138 (6):
41. Beaudoin FL, Merchant RC, Clark MA. Prevalence and detection of prescription opioid misuse and prescription opioid use disorder among emergency department patients 50 years of age and older: performance of the Prescription Drug Use Questionnaire, Patient Version. Am J Geriatr Psychiatry. 2016; 24 (8): 627-636. doi: 10.1016/j.jagp.2016.03.010 27426210
42. Chung T, Colby SM, O'Leary TA, Barnett NP, Monti PM. Screening for cannabis use disorders in an adolescent emergency department sample. Drug Alcohol Depend. 2003; 70 (2): 177-186. doi: 10.1016/S0376-8716(02)00346-0 12732411
43. Rial A, Kim-Harris S, Knight JR, Empirical validation of the CRAFFT abuse screening test in a Spanish sample. Adicciones. 2019; 31 (2): 160-169. doi: 10.20882/adicciones.1105 29353300
44. Legleye S. The Cannabis Abuse Screening Test and the DSM-5 in the general population: optimal thresholds and underlying common structure using multiple factor analysis. Int J Methods Psychiatr Res. 2018; 27 (2):
45. McNeely J, Cleland CM, Strauss SM, Palamar JJ, Rotrosen J, Saitz R. Validation of Self-Administered Single-Item Screening Questions (SISQs) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med. 2015; 30 (12): 1757-1764. doi: 10.1007/s11606-015-3391-6 25986138
46. Wu LT, McNeely J, Subramaniam GA, Sharma G, VanVeldhuisen P, Schwartz RP. Design of the NIDA clinical trials network validation study of Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse (TAPS) tool. Contemp Clin Trials. 2016; 50: 90-97. doi: 10.1016/j.cct.2016.07.013 27444426
47. Tiet QQ, Leyva Y, Moos RH, Smith B. Diagnostic accuracy of a two-item screen for drug use developed from the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Drug Alcohol Depend. 2016; 164: 22-27. doi: 10.1016/j.drugalcdep.2016.03.029 27234660
48. Smith PC, Cheng DM, Allensworth-Davies D, Winter MR, Saitz R. Use of a single alcohol screening question to identify other drug use. Drug Alcohol Depend. 2014; 139: 178-180. doi: 10.1016/j.drugalcdep.2014.03.027 24768061
49. Gryczynski J, McNeely J, Wu LT, Validation of the TAPS-1: a four-item screening tool to identify unhealthy substance use in primary care. J Gen Intern Med. 2017; 32 (9): 990-996. doi: 10.1007/s11606-017-4079-x 28550609
50. Tiet QQ, Leyva YE, Moos RH, Smith B. Diagnostic accuracy of a two-item Drug Abuse Screening Test (DAST-2). Addict Behav. 2017; 74: 112-117. doi: 10.1016/j.addbeh.2017.06.008 28609724
51. Kelly SM, O'Grady KE, Gryczynski J, Mitchell SG, Kirk A, Schwartz RP. The concurrent validity of the Problem Oriented Screening Instrument for Teenagers (POSIT) substance use/abuse subscale in adolescent patients in an urban federally qualified health center. Subst Abus. 2017; 38 (4): 382-388. doi: 10.1080/08897077.2017.1351413 28686545
52. Araujo M, Golpe S, Braña T, Varela J, Rial A. Psychometric validation of the POSIT for screening alcohol and other drugs risk consumption among adolescents. Adicciones. 2018; 30 (2): 130-139. doi: 10.20882/adicciones.958 28492958
53. Sobell LC, Sobell MB. Timeline Followback: A Calendar Method for Assessing Alcohol and Drug Use. Addiction Research Foundation; 1996.
54. D'Amico EJ, Parast L, Shadel WG, Meredith LS, Seelam R, Stein BD. Brief motivational interviewing intervention to reduce alcohol and marijuana use for at-risk adolescents in primary care. J Consult Clin Psychol. 2018; 86 (9): 775-786. doi: 10.1037/ccp0000332 30138016
55. Babor TF, Christiansen K, Donaldson J, Herrel J, Kadden R; Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol. 2004; 72 (3): 455-466. doi: 10.1037/0022-006X.72.3.455 15279529
56. Baker A, Boggs TG, Lewin TJ. Randomized controlled trial of brief cognitive-behavioural interventions among regular users of amphetamine. Addiction. 2001; 96 (9): 1279-1287. doi: 10.1046/j.1360-0443.2001.96912797.x 11672492
57. Baker A, Boggs TG, Lewin TJ. Characteristics of regular amphetamine users and implications for treatment. Drug Alcohol Rev. 2001; 20 (1): 49-56. doi: 10.1080/09595230123756
58. Baker A, Lee NK, Claire M, Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction. 2005; 100 (3): 367-378. doi: 10.1111/j.1360-0443.2005.01002.x 15733250
59. Bonar EE, Walton MA, Barry KL, Sexual HIV risk behavior outcomes of brief interventions for drug use in an inner-city emergency department: secondary outcomes from a randomized controlled trial. Drug Alcohol Depend. 2018; 183: 217-224. doi: 10.1016/j.drugalcdep.2017.10.036 29291549
60. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat. 2001; 20 (1): 45-52. doi: 10.1016/S0740-5472(00)00148-3 11239727
61. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat. 2001; 21 (2): 55-64. doi: 10.1016/S0740-5472(01)00179-9 11551733
62. de Dios MA, Herman DS, Britton WB, Hagerty CE, Anderson BJ, Stein MD. Motivational and mindfulness intervention for young adult female marijuana users. J Subst Abuse Treat. 2012; 42 (1): 56-64. doi: 10.1016/j.jsat.2011.08.001 21940136
63. de Gee EA, Verdurmen JE, Bransen E, de Jonge JM, Schippers GM. A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users. J Subst Abuse Treat. 2014; 47 (3): 181-188. doi: 10.1016/j.jsat.2014.05.001 24969735
64. Dembo R, Briones-Robinson R, Schmeidler J, Brief intervention impact on truant youths' marijuana use: eighteen-month follow-up. J Child Adolesc Subst Abuse. 2016; 25 (1): 18-32. doi: 10.1080/1067828X.2013.872068 28553066
65. Dupont HB, Candel MJ, Kaplan CD, van de Mheen D, de Vries NK. Assessing the efficacy of MOTI-4 for reducing the use of cannabis among youth in the Netherlands: a randomized controlled trial. J Subst Abuse Treat. 2016; 65: 6-12. doi: 10.1016/j.jsat.2015.11.012 26780988
66. Fischer B, Dawe M, McGuire F, Feasibility and impact of brief interventions for frequent cannabis users in Canada. J Subst Abuse Treat. 2013; 44 (1): 132-138. doi: 10.1016/j.jsat.2012.03.006 22520278
67. Fischer B, Jones W, Shuper P, Rehm J. 12-month follow-up of an exploratory "brief intervention" for high-frequency cannabis users among Canadian university students. Subst Abuse Treat Prev Policy. 2012; 7: 15. doi: 10.1186/1747-597X-7-15 22538183
68. Gates PJ, Norberg MM, Copeland J, Digiusto E. Randomized controlled trial of a novel cannabis use intervention delivered by telephone. Addiction. 2012; 107 (12): 2149-2158. doi: 10.1111/j.1360-0443.2012.03953.x 22632139
69. Jones HE, Wong CJ, Tuten M, Stitzer ML. Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers. Drug Alcohol Depend. 2005; 79 (2): 119-128. doi: 10.1016/j.drugalcdep.2005.01.006 16002021
70. Litt MD, Kadden RM, Kabela-Cormier E, Petry NM. Coping skills training and contingency management treatments for marijuana dependence: exploring mechanisms of behavior change. Addiction. 2008; 103 (4): 638-648. doi: 10.1111/j.1360-0443.2008.02137.x 18339108
71. Litt MD, Kadden RM, Petry NM. Behavioral treatment for marijuana dependence: randomized trial of contingency management and self-efficacy enhancement. Addict Behav. 2013; 38 (3): 1764-1775. doi: 10.1016/j.addbeh.2012.08.011 23254227
72. Litt MD, Kadden RM, Stephens RS; Marijuana Treatment Project Research Group. Coping and self-efficacy in marijuana treatment: results from the Marijuana Treatment Project. J Consult Clin Psychol. 2005; 73 (6): 1015-1025. doi: 10.1037/0022-006X.73.6.1015 16392975
73. Lozano BE, Stephens RS, Roffman RA. Abstinence and moderate use goals in the treatment of marijuana dependence. Addiction. 2006; 101 (11): 1589-1597. doi: 10.1111/j.1360-0443.2006.01609.x 17034438
74. Marsden J, Stillwell G, Barlow H, An evaluation of a brief motivational intervention among young ecstasy and cocaine users: no effect on substance and alcohol use outcomes. Addiction. 2006; 101 (7): 1014-1026. doi: 10.1111/j.1360-0443.2006.01290.x 16771893
75. Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abuse Treat. 2008; 34 (4): 407-414. doi: 10.1016/j.jsat.2007.07.004 17869051
76. McCambridge J, Slym RL, Strang J. Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users. Addiction. 2008; 103 (11): 1809-1818. doi: 10.1111/j.1360-0443.2008.02331.x 18778385
77. McCambridge J, Strang J. The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. Addiction. 2004; 99 (1): 39-52. doi: 10.1111/j.1360-0443.2004.00564.x 14678061
78. McCambridge J, Strang J. Deterioration over time in effect of motivational interviewing in reducing drug consumption and related risk among young people. Addiction. 2005; 100 (4): 470-478. doi: 10.1111/j.1360-0443.2005.01013.x 15784061
79. Rooke S, Copeland J, Norberg M, Hine D, McCambridge J. Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial. J Med Internet Res. 2013; 15 (2):
80. Schaub MP, Wenger A, Berg O, A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial. J Med Internet Res. 2015; 17 (10):
81. Stein MD, Herman DS, Anderson BJ. A motivational intervention trial to reduce cocaine use. J Subst Abuse Treat. 2009; 36 (1): 118-125. doi: 10.1016/j.jsat.2008.05.003 18657938
82. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000; 68 (5): 898-908. doi: 10.1037/0022-006X.68.5.898 11068976
83. Stephens RS, Roffman RA, Fearer SA, Williams C, Burke RS. The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction. 2007; 102 (6): 947-957. doi: 10.1111/j.1360-0443.2007.01821.x 17523990
84. Tait RJ, McKetin R, Kay-Lambkin F, Six-month outcomes of a web-based intervention for users of amphetamine-type stimulants: randomized controlled trial. J Med Internet Res. 2015; 17 (4):
85. Bernstein E, Edwards E, Dorfman D, Heeren T, Bliss C, Bernstein J. Screening and brief intervention to reduce marijuana use among youth and young adults in a pediatric emergency department. Acad Emerg Med. 2009; 16 (11): 1174-1185. doi: 10.1111/j.1553-2712.2009.00490.x 20053238
86. Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005; 77 (1): 49-59. doi: 10.1016/j.drugalcdep.2004.07.006 15607841
87. Blow FC, Walton MA, Bohnert ASB, A randomized controlled trial of brief interventions to reduce drug use among adults in a low-income urban emergency department: the HealthiER You study. Addiction. 2017; 112 (8): 1395-1405. doi: 10.1111/add.13773 28127808
88. Bogenschutz MP, Donovan DM, Mandler RN, Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial [published correction appears in JAMA Intern Med. 2015;175(3):470]. JAMA Intern Med. 2014; 174 (11): 1736-1745. doi: 10.1001/jamainternmed.2014.4052 25179753
89. Gelberg L, Andersen RM, Afifi AA, Project QUIT (Quit Using Drugs Intervention Trial): a randomized controlled trial of a primary care-based multi-component brief intervention to reduce risky drug use. Addiction. 2015; 110 (11): 1777-1790. doi: 10.1111/add.12993 26471159
90. Gelberg L, Andersen RM, Rico MW, A pilot replication of QUIT, a randomized controlled trial of a brief intervention for reducing risky drug use, among Latino primary care patients. Drug Alcohol Depend. 2017; 179: 433-440. doi: 10.1016/j.drugalcdep.2017.04.022 28844733
91. Gryczynski J, O'Grady KE, Mitchell SG, Ondersma SJ, Schwartz RP. Immediate versus delayed computerized brief intervention for illicit drug misuse. J Addict Med. 2016; 10 (5): 344-351. doi: 10.1097/ADM.0000000000000248 27504925
92. Humeniuk R, Ali R, Babor T, A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction. 2012; 107 (5): 957-966. doi: 10.1111/j.1360-0443.2011.03740.x 22126102
93. Lee BH, Lim SC, Jeon HJ, Acupuncture suppresses reinstatement of morphine-seeking behavior induced by a complex cue in rats. Neurosci Lett. 2013; 548: 126-131. doi: 10.1016/j.neulet.2013.05.026 23693124
94. Lee CM, Neighbors C, Kilmer JR, Larimer ME. A brief, web-based personalized feedback selective intervention for college student marijuana use: a randomized clinical trial. Psychol Addict Behav. 2010; 24 (2): 265-273. doi: 10.1037/a0018859 20565152
95. Martino S, Ondersma SJ, Forray A, A randomized controlled trial of screening and brief interventions for substance misuse in reproductive health. Am J Obstet Gynecol. 2018; 218 (3): 322.e1-322.e12. doi: 10.1016/j.ajog.2017.12.005 29247636
96. Mason M, Light J, Campbell L, Peer network counseling with urban adolescents: a randomized controlled trial with moderate substance users. J Subst Abuse Treat. 2015; 58: 16-24. doi: 10.1016/j.jsat.2015.06.013 26234955
97. Ondersma SJ, Svikis DS, Schuster CR. Computer-based brief intervention a randomized trial with postpartum women [published correction appears in Am J Prev Med. 2007;32(6):549]. Am J Prev Med. 2007; 32 (3): 231-238. doi: 10.1016/j.amepre.2006.11.003 17236741
98. Ondersma SJ, Svikis DS, Thacker C, Computer-delivered indirect screening and brief intervention for drug use in the perinatal period: a randomized trial. Drug Alcohol Depend. 2018; 185: 271-277. doi: 10.1016/j.drugalcdep.2017.12.022 29482051
99. Ondersma SJ, Svikis DS, Thacker LR, Beatty JR, Lockhart N. Computer-delivered screening and brief intervention (e-SBI) for postpartum drug use: a randomized trial. J Subst Abuse Treat. 2014; 46 (1): 52-59. doi: 10.1016/j.jsat.2013.07.013 24051077
100. Palfai TP, Saitz R, Winter M, Web-based screening and brief intervention for student marijuana use in a university health center: pilot study to examine the implementation of eCHECKUP TO GO in different contexts. Addict Behav. 2014; 39 (9): 1346-1352. doi: 10.1016/j.addbeh.2014.04.025 24845164
101. Poblete F, Barticevic NA, Zuzulich MS, A randomized controlled trial of a brief intervention for alcohol and drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary health care in Chile. Addiction. 2017; 112 (8): 1462-1469. doi: 10.1111/add.13808 28239995
102. Roy-Byrne P, Bumgardner K, Krupski A, Brief intervention for problem drug use in safety-net primary care settings: a randomized clinical trial. JAMA. 2014; 312 (5): 492-501. doi: 10.1001/jama.2014.7860 25096689
103. Saitz R, Cheng DM, Allensworth-Davies D, Winter MR, Smith PC. The ability of single screening questions for unhealthy alcohol and other drug use to identify substance dependence in primary care. J Stud Alcohol Drugs. 2014; 75 (1): 153-157. doi: 10.15288/jsad.2014.75.153 24411807
104. Stein MD, Hagerty CE, Herman DS, Phipps MG, Anderson BJ. A brief marijuana intervention for non-treatment-seeking young adult women. J Subst Abuse Treat. 2011; 40 (2): 189-198. doi: 10.1016/j.jsat.2010.11.001 21185685
105. Tzilos Wernette G, Plegue M, Kahler CW, Sen A, Zlotnick C. A pilot randomized controlled trial of a computer-delivered brief intervention for substance use and risky sex during pregnancy. J Womens Health (Larchmt). 2018; 27 (1): 83-92. doi: 10.1089/jwh.2017.6408 28981379
106. Walton MA, Bohnert K, Resko S, Computer and therapist based brief interventions among cannabis-using adolescents presenting to primary care: one year outcomes. Drug Alcohol Depend. 2013; 132 (3): 646-653. doi: 10.1016/j.drugalcdep.2013.04.020 23711998
107. Watkins KE, Ober AJ, Lamp K, Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial. JAMA Intern Med. 2017; 177 (10): 1480-1488. doi: 10.1001/jamainternmed.2017.3947 28846769
108. Woolard R, Baird J, Longabaugh R, Project reduce: reducing alcohol and marijuana misuse: effects of a brief intervention in the emergency department. Addict Behav. 2013; 38 (3): 1732-1739. doi: 10.1016/j.addbeh.2012.09.006 23261491
109. Yonkers KA, Forray A, Howell HB, Motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice: a randomized trial for treatment of hazardous substance use in pregnancy and after delivery. Gen Hosp Psychiatry. 2012; 34 (5): 439-449. doi: 10.1016/j.genhosppsych.2012.06.002 22795046
110. Zahradnik A, Otto C, Crackau B, Randomized controlled trial of a brief intervention for problematic prescription drug use in non-treatment-seeking patients. Addiction. 2009; 104 (1): 109-117. doi: 10.1111/j.1360-0443.2008.02421.x 19133895
111. Baumeister SE, Gelberg L, Leake BD, Yacenda-Murphy J, Vahidi M, Andersen RM. Effect of a primary care based brief intervention trial among risky drug users on health-related quality of life. Drug Alcohol Depend. 2014; 142: 254-261. doi: 10.1016/j.drugalcdep.2014.06.034 25042213
112. Bogenschutz MP, Donovan DM, Adinoff B, Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED). Am J Drug Alcohol Abuse. 2011; 37 (5): 417-425. doi: 10.3109/00952990.2011.596971 21854285
113. Fuster D, Cheng DM, Wang N, Brief intervention for daily marijuana users identified by screening in primary care: a subgroup analysis of the ASPIRE randomized clinical trial. Subst Abus. 2016; 37 (2): 336-342. doi: 10.1080/08897077.2015.1075932 26453188
114. Kim TW, Bernstein J, Cheng DM, Receipt of addiction treatment as a consequence of a brief intervention for drug use in primary care: a randomized trial. Addiction. 2017; 112 (5): 818-827. doi: 10.1111/add.13701 27886657
115. Krupski A, Joesch JM, Dunn C, Testing the effects of brief intervention in primary care for problem drug use in a randomized controlled trial: rationale, design, and methods. Addict Sci Clin Pract. 2012; 7: 27. doi: 10.1186/1940-0640-7-27 23237456
116. Mason MJ, Sabo R, Zaharakis NM. Peer network counseling as brief treatment for urban adolescent heavy cannabis users. J Stud Alcohol Drugs. 2017; 78 (1): 152-157. doi: 10.15288/jsad.2017.78.152 27936376
117. Otto C, Crackau B, Löhrmann I, Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. Drug Alcohol Depend. 2009; 105 (3): 221-226. doi: 10.1016/j.drugalcdep.2009.07.010 19726140
118. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav. 2007; 32 (6): 1220-1236. doi: 10.1016/j.addbeh.2006.08.009 16996224
119. Saitz R, Palfai TP, Cheng DM, Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014; 312 (5): 502-513. doi: 10.1001/jama.2014.7862 25096690
120. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008; 94 (1-3): 199-206. doi: 10.1016/j.drugalcdep.2007.11.021 18243585
121. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003; 361 (9358): 662-668. doi: 10.1016/S0140-6736(03)12600-1 12606177
122. Krook AL, Brørs O, Dahlberg J, A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002; 97 (5): 533-542. doi: 10.1046/j.1360-0443.2002.00090.x 12033654
123. Ling W, Casadonte P, Bigelow G, Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010; 304 (14): 1576-1583. doi: 10.1001/jama.2010.1427 20940383
124. Rosenthal RN, Ling W, Casadonte P, Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013; 108 (12): 2141-2149. doi: 10.1111/add.12315 23919595
125. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371 (9631): 2192-2200. doi: 10.1016/S0140-6736(08)60954-X 18586174
126. Schwartz RP, Highfield DA, Jaffe JH, A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006; 63 (1): 102-109. doi: 10.1001/archpsyc.63.1.102 16389204
127. Schwartz RP, Jaffe JH, Highfield DA, Callaman JM, O'Grady KE. A randomized controlled trial of interim methadone maintenance: 10-month follow-up. Drug Alcohol Depend. 2007; 86 (1): 30-36. doi: 10.1016/j.drugalcdep.2006.04.017 16793221
128. Schwartz RP, Jaffe JH, O'Grady KE, Interim methadone treatment: impact on arrests. Drug Alcohol Depend. 2009; 103 (3): 148-154. doi: 10.1016/j.drugalcdep.2009.03.007 19443133
129. Cornish JW, Metzger D, Woody GE, Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997; 14 (6): 529-534. doi: 10.1016/S0740-5472(97)00020-2 9437624
130. Guo S, Jiang Z, Wu Y. Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification. Hong Kong J Paediatr. 2001; 11 (4): 2-9.
131. Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals: report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry. 1978; 35 (3): 335-340. doi: 10.1001/archpsyc.1978.01770270085008 365122
132. Krupitsky EM, Zvartau EE, Masalov DV, Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004; 26 (4): 285-294. doi: 10.1016/j.jsat.2004.02.002 15182893
133. Krupitsky EM, Zvartau EE, Masalov DV, Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006; 31 (4): 319-328. doi: 10.1016/j.jsat.2006.05.005 17084785
134. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377 (9776): 1506-1513. doi: 10.1016/S0140-6736(11)60358-9 21529928
135. Krupitsky E, Zvartau E, Blokhina E, Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012; 69 (9): 973-981. doi: 10.1001/archgenpsychiatry.2012.1a 22945623
136. Krupitsky E, Zvartau E, Blokhina E, Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St. Petersburg, Russia. Drug Alcohol Depend. 2013; 132 (3): 674-680. doi: 10.1016/j.drugalcdep.2013.04.021 23683793
137. Krupitsky E, Zvartau E, Blokhina E, Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse. 2016; 42 (5): 614-620. doi: 10.1080/00952990.2016.1197231 27436632
138. Lerner A, Sigal M, Bacalu A, Shiff R, Burganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci. 1992; 29 (1): 36-43. 1568861
139. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict. 1991; 86 (8): 983-990. doi: 10.1111/j.1360-0443.1991.tb01859.x 1912753
140. Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 1994; 35 (12): 935-945. doi: 10.1016/0006-3223(94)91240-8 8080893
141. Stella L, D'Ambra C, Mazzeo F, Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients. Life Sci. 2005; 77 (21): 2717-2722. doi: 10.1016/j.lfs.2005.05.036 15979652
142. Lee CM, Kilmer JR, Neighbors C, Indicated prevention for college student marijuana use: a randomized controlled trial. J Consult Clin Psychol. 2013; 81 (4): 702-709. doi: 10.1037/a0033285 23750464
143. National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services. Resource guide: screening for drug use in general medical settings. Accessed September 11, 2017. https://www.drugabuse.gov/sites/default/files/resource-guide.pdf
144. American Society of Addiction Medicine. The national practice guideline for the use of medications in the treatment of addiction involving opioid use. Updated 2015. Accessed April 26, 2019. https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf
145. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014; 8 (3): 153-163. doi: 10.1097/ADM.0000000000000034 24874759
146. Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol. 2015; 2 (1): 10. doi: 10.1186/s40621-015-0041-8 27747742